Download PDF
Semin Thromb Hemost 2019; 45(07): 730-742
DOI: 10.1055/s-0039-1694772
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Genetic Testing for Thrombophilia-Related Genes: Observations of Testing Patterns for Factor V Leiden (G1691A) and Prothrombin Gene “Mutation” (G20210A)

Emmanuel J. Favaloro
1   Department of Haematology, Institute of Clinical Pathology and Medical Research, NSW Health Pathology, Westmead Hospital, Westmead, New South Wales, Australia
2   Sydney Centres for Thrombosis and Haemostasis, Westmead, New South Wales, Australia
› Author Affiliations
Further Information

Publication History

Publication Date:
09 August 2019 (online)

    Permissions and Reprints

Abstract

Thrombophilia is a generic term that defines an increased propensity toward thrombosis and associated morbidity. Factor V Leiden (FVL; G1691A) and the prothrombin gene mutation (PGM; G20210A) comprise the most common genetic associations with thrombosis, and thus comprise the most commonly requested genetic thrombophilia investigations. This report describes an audit of local test findings that suggests growing futility in testing for FVL and PGM. Test requests for FVL and PGM were assessed for a recent period of 2.5 years (starting from 2016 to end of June 2018) from a large tertiary-level pathology provider. From a total of more than 10,000 thrombophilia-related test requests over the analysis period, 2,700 and 2,135 were, respectively, for FVL and PGM. The age ranges of patients varied across the full life span spectrum, but the peak investigation age range for the entire cohort was 30 to 39 years. Investigations were more often requested for females (> 70% of requests) than males, and the peak investigation age range for females (30–39 years) was earlier than males (50–59 years). However, proportionally more males than females were identified with FVL (15.4 vs. 6.6%) or PGM (10.4 vs. 4.3%), respectively. The age-related patterns of test ordering were also identified as closely aligned to birth patterns in females and thrombosis patterns in males. There has been a trend to annual reduction in detection of FVL mutation from a peak of more than 25% in 1996 to ∼10% in each year of the past decade, suggesting poorer patient selection. Of test-requesting indications, pregnancy/fetal morbidity was identified in 16.4% of all requests for females, and thromboembolism was identified in 21.4 and 18.0% of all requests for females and males, respectively. In terms of FVL identification, a heterozygous pattern was identified in 4.2% of women tested for pregnancy/fetal morbidity, but 11.7 and 15.1% of females and males, respectively, for thromboembolism. In comparison, the background rate of FVL detection in the general population in our geographical region is approximately 3 to 7%. Overall, better targeted patient selection for testing of FVL and PGM occurred in the male cohort based on higher relative capture of thrombophilia mutations than the female cohort. However, patient selection was not optimal in either the male or female cohorts, since the captured mutation rates were only marginally higher than the expected background population detection rate. Moreover, the decline in relative identification of FVL from overall test requests over time suggests deterioration of patient selection practices by referring physicians. Notably, tests requested in the setting of thromboembolism provided a higher likelihood of FVL detection than pregnancy/fetal morbidity. These data suggest some contemporary futility of genetic testing for FVL and PGM in the real world, and in particular, in females for indications around pregnancy/fetal morbidity, proposed to be related to poor patient selection in most instances.

Keywords

thrombophilia - factor V Leiden - FVL - Arg506Gln - R506Q - G1691A - prothrombin gene mutation - PGM - G20210A - laboratory practice
 

  • References

  • 1 Salvagno GL, Pavan C, Lippi G. Rare thrombophilic conditions. Ann Transl Med 2018; 6 (17) 342
    CrossrefPubMedGoogle Scholar
  • 2 Favaloro EJ, Wong RCW. Antiphospholipid antibody testing for the antiphospholipid syndrome: a comprehensive practical review including a synopsis of challenges and recent guidelines. Pathology 2014; 46 (06) 481-495
    CrossrefPubMedGoogle Scholar
  • 3 Middeldorp S. Inherited thrombophilia: a double-edged sword. Hematology (Am Soc Hematol Educ Program) 2016; 2016 (01) 1-9
    CrossrefPubMedGoogle Scholar
  • 4 Montagnana M, Lippi G, Danese E. An overview of thrombophilia and associated laboratory testing. Methods Mol Biol 2017; 1646: 113-135
    CrossrefPubMedGoogle Scholar
  • 5 Van Cott EM, Khor B, Zehnder JL. Factor V Leiden. Am J Hematol 2016; 91 (01) 46-49
    CrossrefPubMedGoogle Scholar
  • 6 Baglin T, Gray E, Greaves M. , et al; British Committee for Standards in Haematology. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol 2010; 149 (02) 209-220
    CrossrefPubMedGoogle Scholar
  • 7 Graham N, Rashiq H, Hunt BJ. Testing for thrombophilia: clinical update. Br J Gen Pract 2014; 64 (619) e120-e122
    CrossrefPubMedGoogle Scholar
  • 8 Howard LS, Hughes RJ. NICE guideline: management of venous thromboembolic diseases and role of thrombophilia testing. Thorax 2013; 68 (04) 391-393
    CrossrefPubMedGoogle Scholar
  • 9 De Stefano V, Rossi E. Testing for inherited thrombophilia and consequences for antithrombotic prophylaxis in patients with venous thromboembolism and their relatives. A review of the Guidelines from Scientific Societies and Working Groups. Thromb Haemost 2013; 110 (04) 697-705
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Carroll BJ, Piazza G. Hypercoagulable states in arterial and venous thrombosis: when, how, and who to test?. Vasc Med 2018; 23 (04) 388-399
    CrossrefPubMedGoogle Scholar
  • 11 Ormesher L, Simcox LE, Tower C, Greer IA. ‘To test or not to test’, the arguments for and against thrombophilia testing in obstetrics. Obstet Med 2017; 10 (02) 61-66
    CrossrefPubMedGoogle Scholar
  • 12 Davenport WB, Kutteh WH. Inherited thrombophilias and adverse pregnancy outcomes: a review of screening patterns and recommendations. Obstet Gynecol Clin North Am 2014; 41 (01) 133-144
    CrossrefPubMedGoogle Scholar
  • 13 Lopes L, Jacob GP. Thrombophilia testing in pregnancy: should we agree to disagree?. J Perinat Med 2015; 43 (02) 269-272
    PubMedGoogle Scholar
  • 14 Favaloro EJ. Diagnostic issues in thrombophilia: a laboratory scientist's view. Semin Thromb Hemost 2005; 31 (01) 11-16
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346 (8983): 1133-1134
    CrossrefPubMedGoogle Scholar
  • 16 Pecheniuk NM, Marsh NA, Walsh TP, Dale JL. Use of first nucleotide change technology to determine the frequency of factor V Leiden in a population of Australian blood donors. Blood Coagul Fibrinolysis 1997; 8 (08) 491-495
    CrossrefPubMedGoogle Scholar
  • 17 Lee DH, Henderson PA, Blajchman MA. Prevalence of factor V Leiden in a Canadian blood donor population. CMAJ 1996; 155 (03) 285-289
    PubMedGoogle Scholar
  • 18 Larsen TB, Lassen JF, Brandslund I, Byriel L, Petersen GB, Nørgaard-Pedersen B. The Arg506Gln mutation (FV Leiden) among a cohort of 4188 unselected Danish newborns. Thromb Res 1998; 89 (05) 211-215
    CrossrefPubMedGoogle Scholar
  • 19 Herrmann FH, Koesling M, Schrŏder W. , et al. Prevalence of factor V Leiden mutation in various populations. Genet Epidemiol 1997; 14 (04) 403-411
    CrossrefPubMedGoogle Scholar
  • 20 Schröder W, Koesling M, Wulff K, Wehnert M, Herrmann FH. Large-scale screening for factor V Leiden mutation in a north-eastern German population. Haemostasis 1996; 26 (05) 233-236
    PubMedGoogle Scholar
  • 21 Cumming AM, Keeney S, Salden A, Bhavnani M, Shwe KH, Hay CR. The prothrombin gene G20210A variant: prevalence in a U.K. anticoagulant clinic population. Br J Haematol 1997; 98 (02) 353-355
    CrossrefPubMedGoogle Scholar
  • 22 Bowen DJ, Bowley S, John M, Collins PW. Factor V Leiden (G1691A), the prothrombin 3′-untranslated region variant (G20210A) and thermolabile methylenetetrahydrofolate reductase (C677T): a single genetic test genotypes all three loci--determination of frequencies in the S. Wales population of the UK. Thromb Haemost 1998; 79 (05) 949-954
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Nasiruddin, Zahur-ur-Rehman, Anwar M, Ahmed S, Ayyub M, Ali W. Frequency of factor V Leiden mutation. J Coll Physicians Surg Pak 2005; 15 (01) 15-17
    PubMedGoogle Scholar
  • 24 Arruda VR, Annichino-Bizzacchi JM, Costa FF, Reitsma PH. Factor V Leiden (FVQ 506) is common in a Brazilian population. Am J Hematol 1995; 49 (03) 242-243
    CrossrefPubMedGoogle Scholar
  • 25 Gürgey A, Mesci L. The prevalence of factor V Leiden (1691 G-->A) mutation in Turkey. Turk J Pediatr 1997; 39 (03) 313-315
    PubMedGoogle Scholar
  • 26 Gregg JP, Yamane AJ, Grody WW. Prevalence of the factor V-Leiden mutation in four distinct American ethnic populations. Am J Med Genet 1997; 73 (03) 334-336
    CrossrefPubMedGoogle Scholar
  • 27 Ruiz-Argüelles GJ, Garcés-Eisele J, Reyes-Núñez V, Ramírez-Cisneros FJ. Primary thrombophilia in Mexico. II. Factor V G1691A (Leiden), prothrombin G20210A, and methylenetetrahydrofolate reductase C677T polymorphism in thrombophilic Mexican mestizos. Am J Hematol 2001; 66 (01) 28-31
    CrossrefPubMedGoogle Scholar
  • 28 Abdulkadir J, Feleke Y, Berg JP, Falch JA, Odegaard OR. Absence of the factor V Leiden mutation in Ethiopians. Thromb Res 1997; 86 (05) 431-432
    CrossrefPubMedGoogle Scholar
  • 29 Angchaisuksiri P, Pingsuthiwong S, Aryuchai K. , et al. Prevalence of the G1691A mutation in the factor V gene (factor V Leiden) and the G20210A prothrombin gene mutation in the Thai population. Am J Hematol 2000; 65 (02) 119-122
    CrossrefPubMedGoogle Scholar
  • 30 Pepe G, Rickards O, Vanegas OC. , et al. Prevalence of factor V Leiden mutation in non-European populations. Thromb Haemost 1997; 77 (02) 329-331
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Ho CH, Chau WK, Hsu HC, Gau JP, Chih CM. Prevalence of factor V Leiden in the Chinese population. Zhonghua Yi Xue Za Zhi (Taipei) 1999; 62 (12) 875-878
    PubMedGoogle Scholar
  • 32 Gupta N, Khan F, Tripathi M. , et al. Absence of factor V Leiden (G1691A) mutation, FII G20210A allele in coronary artery disease in North India. Indian J Med Sci 2003; 57 (12) 535-542
    PubMedGoogle Scholar
  • 33 Kim YW, Yoon KY, Park S, Shim YS, Cho HI, Park SS. Absence of factor V Leiden mutation in Koreans. Thromb Res 1997; 86 (02) 181-182
    CrossrefPubMedGoogle Scholar
  • 34 Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA 1997; 277 (16) 1305-1307
    CrossrefPubMedGoogle Scholar
  • 35 Irani-Hakime N, Tamim H, Kreidy R, Almawi WY. The prevalence of factor V R506Q mutation-Leiden among apparently healthy Lebanese. Am J Hematol 2000; 65 (01) 45-49
    CrossrefPubMedGoogle Scholar
  • 36 Arachchillage DRJ, Makris M. Inherited thrombophilia and pregnancy complications: should we test?. Semin Thromb Hemost 2019; 45 (01) 50-60
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Othman M, McLintock C, Kadir R. Thrombosis and hemostasis related issues in women and pregnancy. Semin Thromb Hemost 2016; 42 (07) 693-695
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Aznar J, Vayá A, Estellés A. , et al. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives. Haematologica 2000; 85 (12) 1271-1276
    PubMedGoogle Scholar
  • 39 Favaloro EJ, McDonald D. Futility of testing for factor V Leiden. Blood Transfus 2012; 10 (03) 260-263
    PubMedGoogle Scholar
  • 40 Favaloro EJ. Danger of false negative (exclusion) or false positive (diagnosis) for ‘congenital thrombophilia’ in the age of anticoagulants. Clin Chem Lab Med 2019; 57 (06) 873-882
    CrossrefPubMedGoogle Scholar
  • 41 Favaloro EJ, Mohammed S, Curnow J, Pasalic L. Laboratory testing for lupus anticoagulant (LA) in patients taking direct oral anticoagulants (DOACs): potential for false positives and false negatives. Pathology 2019; 51 (03) 292-300
    CrossrefPubMedGoogle Scholar
  • 42 Summary of 2016 statistics related to demographics of the New South Wales population. Available at: https://quickstats.censusdata.abs.gov.au/census_services/getproduct/census/2016/quickstat/1 . Accessed May 2, 2019
    PubMedGoogle Scholar
  • 43 Bloomenthal D, von Dadelszen P, Liston R, Magee L, Tsang P. The effect of factor V Leiden carriage on maternal and fetal health. CMAJ 2002; 167 (01) 48-54
    PubMedGoogle Scholar
  • 44 Said JM, Higgins JR, Moses EK, Walker SP, Monagle PT, Brennecke SP. Inherited thrombophilias and adverse pregnancy outcomes: a case-control study in an Australian population. Acta Obstet Gynecol Scand 2012; 91 (02) 250-255
    CrossrefPubMedGoogle Scholar
  • 45 Kjellberg U, van Rooijen M, Bremme K, Hellgren M. Factor V Leiden mutation and pregnancy-related complications. Am J Obstet Gynecol 2010; 203 (05) 469.e1-469.e8
    CrossrefPubMedGoogle Scholar
  • 46 Croles FN, Nasserinejad K, Duvekot JJ, Kruip MJ, Meijer K, Leebeek FW. Pregnancy, thrombophilia, and the risk of a first venous thrombosis: systematic review and bayesian meta-analysis. BMJ 2017; 359: j4452
    Google Scholar
  • 47 Barut MU, Bozkurt M, Kahraman M. , et al. Thrombophilia and recurrent pregnancy loss: the enigma continues. Med Sci Monit 2018; 24: 4288-4294
    CrossrefPubMedGoogle Scholar
  • 48 Jusić A, Balić D, Avdić A, Pođanin M, Balić A. The association of factor V G1961A (factor V Leiden), prothrombin G20210A, MTHFR C677T and PAI-1 4G/5G polymorphisms with recurrent pregnancy loss in Bosnian women. Med Glas (Zenica) 2018; 15 (02) 158-163
    PubMedGoogle Scholar
  • 49 Kardi MT, Yousefian E, Allahveisi A, Alaee S. Association of factor V Leiden and prothrombin G20210A polymorphisms in women with recurrent pregnancy loss in Isfahan Province, Iran. Int J Prev Med 2018; 9: 13
    CrossrefPubMedGoogle Scholar
  • 50 Chatzidimitriou M, Chatzidimitriou D, Mavridou M. , et al. Thrombophilic gene polymorphisms and recurrent pregnancy loss in Greek women. Int J Lab Hematol 2017; 39 (06) 590-595
    CrossrefPubMedGoogle Scholar
  • 51 Sergi C, Al Jishi T, Walker M. Factor V Leiden mutation in women with early recurrent pregnancy loss: a meta-analysis and systematic review of the causal association. Arch Gynecol Obstet 2015; 291 (03) 671-679
    CrossrefPubMedGoogle Scholar
  • 52 Ziakas PD, Poulou LS, Pavlou M, Zintzaras E. Thrombophilia and venous thromboembolism in pregnancy: a meta-analysis of genetic risk. Eur J Obstet Gynecol Reprod Biol 2015; 191: 106-111
    CrossrefPubMedGoogle Scholar
  • 53 Crispin P, Koo RM. Genetic and molecular testing in thrombosis and hemostasis: informing surveillance, treatment and prognosis. Semin Thromb Hemost 2019; 45 (07) 720-729
    Article in Thieme ConnectPubMedGoogle Scholar
  • 54 D'Andrea E, Lagerberg T, De Vito C. , et al. Patient experience and utility of genetic information: a cross-sectional study among patients tested for cancer susceptibility and thrombophilia. Eur J Hum Genet 2018; 26 (04) 518-526
    PubMedGoogle Scholar
  • 55 Page JM, Silver RM. Genetic causes of recurrent pregnancy loss. Clin Obstet Gynecol 2016; 59 (03) 498-508
    CrossrefPubMedGoogle Scholar
  • 56 Hüttel E, Padberg S, Meister R, Beck E, Schaefer C. Pregnancy outcome of first trimester exposure to the vitamin K antagonist phenprocoumon depends on duration of treatment. Thromb Haemost 2017; 117 (05) 870-879
    Article in Thieme ConnectPubMedGoogle Scholar
  • 57 International Society on Thrombosis and Haemostasis (ISTH) Scientific Standardisation Committee (SSC) on Women's Health international registry. Available at: https://redcap.isth.org/surveys/?s=P99ARFCM3J . Accessed May 2, 2019
    PubMed
  • 58 Rodger MA, Hague WM, Kingdom J. , et al; TIPPS Investigators. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet 2014; 384 (9955): 1673-1683
    CrossrefPubMedGoogle Scholar
  • 59 Lippi G. Thrombophilia testing. Useful or hype?. Clin Chem Lab Med 2014; 52 (04) 467-469
    PubMedGoogle Scholar
  • 60 Franchini M. The utility of thrombophilia testing. Clin Chem Lab Med 2014; 52 (04) 495-497
    PubMedGoogle Scholar
  • 61 Favaloro EJ. The futility of thrombophilia testing. Clin Chem Lab Med 2014; 52 (04) 499-503
    PubMedGoogle Scholar
  • 62 Hillis CM, Schimmer AD, Couban S, Crowther MA. The Canadian Choosing Wisely campaign: the Canadian Hematology Society's top five tests and treatments. Ann Hematol 2015; 94 (04) 541-545
    CrossrefPubMedGoogle Scholar
  • 63 Lussana F, de Rooij SR, Veenendaal M. , et al. Prevalence of factor V Leiden and G20210A prothrombin mutation in the Dutch Famine Birth Cohort: a possible survival advantage?. Thromb Haemost 2012; 108 (02) 399-401
    Article in Thieme ConnectPubMedGoogle Scholar
  • 64 Franchini M, Lippi G. Factor V Leiden and hemophilia. Thromb Res 2010; 125 (02) 119-123
    CrossrefPubMedGoogle Scholar
  • 65 Lindqvist PG, Dahlbäck B. Carriership of factor V Leiden and evolutionary selection advantage. Curr Med Chem 2008; 15 (15) 1541-1544
    CrossrefPubMedGoogle Scholar